Delgoffe lab shows in Cancer Immunology Research that the type II diabetes drug metformin improves immunotherapy

The laboratory of Greg M. Delgoffe, Assistant Professor of Immunology, has published an article in Cancer Immunology Research demonstrating a role for the type II diabetes drug metformin in the metabolic remodeling of the tumor microenvironment. Treatment of mouse tumor models with this common metabolic drug results in enhanced response to PD-1 blockade mediated immunotherapy.

The article, entitled, "Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia," can be found here.